Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors

Journal of Neuro-Oncology

Volumn 125, Issue 2, 2015, Pages 249-251

  Chamberlain, Marc C ^a,c   Born, Donald ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Oligodendroglioma; Polysomy; Relative1p 19q codeletion

Indexed keywords

ARTICLE; CANCER GRADING; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CHROMOSOME NUMBER; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; OLIGODENDROGLIOMA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; BRAIN NEOPLASMS; CHROMOSOME 1; CHROMOSOME 19; CLASSIFICATION; FEMALE; GENETICS; MALE; PROGNOSIS;

BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; OLIGODENDROGLIOMA; PROGNOSIS;

EID: 84945444401     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1906-y     Document Type: Article

References (12)

1. Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479
2. Jenkins RB, Blair H, Ballman KV et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861
3. Cairncross G, Wang M, Shaw E, Jenkins R et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343
4. van den Bent MJ, Brandes AA, Taphoorn MJB et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350
5. Buckner J, Shaw E, Pugh S, et al. R9802: Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: Results by histologic type. Neuro Oncol 2014;16 (suppl5): AT-13. Abstract
6. Snuderl M, Echler AF, Ligon KL et al (2009) Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res 15:6430–6437
7. Al Wiens, Cheng L, Bertsch EC et al (2012) Polysomy of chromosomes 1 and or 19 is common and associated with less favorable clinical outcome in oligodendrogliomas: fluorescent in situ hybridization analysis of 84 consecutive cases. J Neuropathol Exp Neurol 71:618–624
8. Ren X, Jiang H, Cui X et al (2013) Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases. Neuro Oncol 15:1244–1250
9. Jiang H, Ren X, Zhang Z, Zeng W, Wang J, Lin S (2014) Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors. J Neurooncol 120:131–138
10. Reifenberger G, Kros JM, Louis DN et al (2007) Oligodendroglioma and anaplastic oligodendroglioma. In: Louis DN, Ohgaki H, Wiestler OD et al (eds) WHO classification of tumours of the central nervous system. IARC Press, Lyon, France, pp 54–62
11. Fallon KB, Palmer CA, Roth KA et al (2004) Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314–322
12. Weller M, Wick W (2014) Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma. Nat Rev Neurol 10:68–70